UV9-19025-91026
2 vaccinations
3 coded responses
23 check-ins
3 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 51-55
- ZIP prefix
- 021 / MA
- Registered
- 2021-04-25
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Registered dependents
BLA-20515-71694
Child or adolescent in my care · Male · 2021-06-12
Timeline
-
2021-04-25
Registered in v-safe
-
2021-04-25
Dose 1 — Pfizer-BioNTech
- 2021-04-25
-
2021-04-26
Survey response — days 1–6 daily, dose 1MedDRA: Injection site pain, Myalgia — Feeling: Good · Site: Pain · Muscle or body achesFree text: muscle/body aches are in the upper arm where received injection.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-04-27
- 2021-04-29
- 2021-04-30
- 2021-05-01
- 2021-05-02
- 2021-05-10
-
2021-05-16
Dose 2 — Pfizer-BioNTech
- 2021-05-16
-
2021-05-17
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to work, Be unable to do your normal daily activitiesAdult check-in
- 2021-05-18
- 2021-05-19
- 2021-05-20
- 2021-05-21
- 2021-05-22
- 2021-05-23
- 2021-05-30
- 2021-06-06
- 2021-06-13
- 2021-06-27
-
2021-08-15
Survey response — 3 months, dose 2MedDRA: Hyperacusis, Migraine, Photophobia, Pre-existing disease — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · HospitalizationFree text: Persistent severe migraine exacerbation with hyperacusis and now photophobia.MedDRA releases: 2021-09,2024-11 · check-in free text available
-
2021-08-15
Report sent to call center — 3 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare pr1 call case(s)
- 2021-10-08
-
2021-10-13
Call successfulNot applicable - Accidental Reporting
- 2021-11-14
-
2022-05-16
Survey response — 12 months, dose 2MedDRA: Malaise, SARS-CoV-2 test positive — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: COVID-19 illness symptom onset April 18, confirmed by rapid test.MedDRA releases: 2024-11 · check-in free text available
-
2022-05-16
Report sent to call center — 12 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2022-05-17
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-25 | Pfizer-BioNTech | |
| 2 | 2021-05-16 | Pfizer-BioNTech |
Call center
2 call center cases
1 successful · 1 unsuccessful
Free text
Release 8 — days 1–6 daily, dose 1
Systemic reaction (other): muscle/body aches are in the upper arm where received injection.
Release 9 — 3 months, dose 2
Symptoms: Persistent severe migraine exacerbation with hyperacusis and now photophobia.
Release 11 — 12 months, dose 2
Symptoms: COVID-19 illness symptom onset April 18, confirmed by rapid test.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Hyperacusis | ✓ | · | ✓ |
| SD | Malaise | · | · | ✓ |
| SD | Migraine | ✓ | · | ✓ |
| SD | Photophobia | ✓ | · | ✓ |
| SD | Pre-existing disease | ✓ | · | ✓ |
| SD | SARS-CoV-2 test positive | · | · | ✓ |
| SRO | Injection site pain | ✓ | ✓ | ✓ |
| SRO | Myalgia | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release